Country
Full text data for US,EP,CN
Type
Legal Validity
Legal Status
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC(Section)
IPC(Class)
IPC(Subclass)
IPC(Group)
IPC(Subgroup)
LOC
Agent
Agency
Claims Number
Figures Number
Citation Number of Times
Assignee Number
No. Publication Number Title Publication/Patent Number Publication/Patent Number Publication Date Publication Date
Application Number Application Number Filing Date Filing Date
Inventor Inventor Assignee Assignee IPC IPC
1
EP3790567A1
LIVER-SPECIFIC TROPISM OF ADENO-ASSOCIATED VIRUSES
Publication/Patent Number: EP3790567A1 Publication Date: 2021-03-17 Application Number: 19799988.1 Filing Date: 2019-05-10 Inventor: Vandenberghe, Luk H.   Schmit, Pauline   Tipper, Christopher   Unzu, Carmen   Zinn, Eric   Assignee: Massachusetts Eye and Ear Infirmary   The Schepens Eye Research Institute, Inc.   IPC: A61K35/76
2
US2021290702A1
BACTERIOPHAGE PREPARATION
Publication/Patent Number: US2021290702A1 Publication Date: 2021-09-23 Application Number: 17/266,232 Filing Date: 2019-08-09 Inventor: Iwano, Hidetomo   Higuchi, Hidetoshi   Tamura, Yutaka   Usui, Masaru   Fujiki, Jumpei   Assignee: MEIJI SEIKA PHARMA CO., LTD.   INCORPORATED EDUCATIONAL INSTITUTION RAKUNO GAKUEN   IPC: A61K35/76 Abstract: It has been found that a bacteriophage specified by accession number NITE BP-693 and a bacteriophage specified by accession number NITE BP-694 have lytic activity against Staphylococcus hyicus, Staphylococcus chromogenes, and the like, which has made it possible to provide a composition for lysing these staphylococci, a composition for treating or preventing a disease caused by these staphylococci, and the like.
3
EP3781186A1
BACTERIOPHAGE COMPOSITIONS
Publication/Patent Number: EP3781186A1 Publication Date: 2021-02-24 Application Number: 19721553.6 Filing Date: 2019-04-17 Inventor: Rast, Markus   Rodriguez, Morillas Sergio   Iida, Tomomine   Assignee: Takeda GmbH   Takeda Pharmaceutical Company Limited   IPC: A61K35/76
4
CN109769748B
戊型肝炎病毒慢性化小鼠模型的构建方法
Grant
Publication/Patent Number: CN109769748B Publication Date: 2021-07-06 Application Number: 201910127893.9 Filing Date: 2019-02-21 Inventor: 黄芬   郝先辉   禹文海   李云龙   Assignee: 昆明理工大学   IPC: A01K67/02 Abstract: 本发明公开了一种戊型肝炎病毒慢性化小鼠模型的构建方法;本方法中HEV毒株来源于慢性化感染恒河猴粪便,该恒河猴持续排毒93周;通过尾静脉将HEV病毒悬液接种BALB/c小鼠后,在小鼠粪便和血清中能够持续检测到HEV RNA,且具有较高的病毒拷贝,此外持续阳性时间可达36周;本发明建立模型的方法简单,可用于HEV持续性感染机制的研究,并为抗HEV药物筛选及评估提供重要的动物模型。
5
US2021308198A1
COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF PATHOGENIC ESCHERICHIA COLI
Publication/Patent Number: US2021308198A1 Publication Date: 2021-10-07 Application Number: 16/840,334 Filing Date: 2020-04-04 Inventor: Yoon, Seong Jun   Son, Jee Soo   Kim, In Hwang   Paik, Hyoung Rok   Im, Hyun Joo   Park, Ji Young   Yu, Hyun Jin   Seo, Ji Yeong   Jun, Soo Youn   Kang, Sang Hyeon   Assignee: iNtRON Biotechnology, Inc.   IPC: A61K35/76 Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.
6
US2021205380A1
ANTIBACTERIAL PHAGE, THERAPEUTIC COMPOSITION, BACTERICIDAL AGENT, FOOD, BACTERIA IDENTIFICATION KIT, THERAPEUTIC COMPOSITION MANUFACTURING METHOD, BACTERIA ELIMINATION METHOD, BACTERIA IDENTIFICATION METHOD, AND ANIMAL THERAPEUTIC METHOD
Publication/Patent Number: US2021205380A1 Publication Date: 2021-07-08 Application Number: 17/057,678 Filing Date: 2019-04-19 Inventor: Cui, Longzhu   Kiga, Kotaro   Assignee: JICHI MEDICAL UNIVERSITY   IPC: A61K35/76 Abstract: Provided are antibacterial phages that selectively kill bacteria having a drug resistance gene or the like. Antibacterial phage for this includes CRISPR-Cas13a with a target sequence that recognizes a specific gene as a target. This target sequence is designed as a spacer sequence for crRNA of 14-28 bases. Specific genes are drug resistance genes and toxins. The drug resistance genes are included in bacterial genomes and/or plasmids having one or any combination of the group including: methicillin-resistant Staphylococcus aureus, vancomycin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, penicillin-resistant pneumococcus, multidrug-resistant Pseudomonas aeruginosa, multidrug-resistant Pseudomonas aeruginosa, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant cephalosporins, third-generation cephalosporin-resistant Pseudomonas aeruginosa, third-generation cephalosporin-resistant E. coli, and fluoroquinolone-resistant E. coli.
7
EP3796982A1
ECHO-7 ONCOLYTIC VIRUS FOR USE IN THE TREATMENT OF UVEAL MELANOMA
Publication/Patent Number: EP3796982A1 Publication Date: 2021-03-31 Application Number: 19731600.3 Filing Date: 2019-05-23 Inventor: Venskus, Dite   Kalvins, Ivars   Alberts, Peteris   Urbans, Karlis   Auzins, Jurgis   Assignee: Ditesan Ltd.   IPC: A61P35/00
8
US2021093580A1
NANOSCALE COATINGS FOR ENCAPSULATION OF BIOLOGICAL ENTITIES
Publication/Patent Number: US2021093580A1 Publication Date: 2021-04-01 Application Number: 17/118,509 Filing Date: 2020-12-10 Inventor: Ortac, Inanc   Yong, Gen   Benchimol, Michael   Esener, Sadik C.   Assignee: The Regents of the University of California   IPC: A61K9/51 Abstract: Methods, systems, and devices are disclosed for encapsulating biological entities with preservation of their biological activity. In one aspect, a method of encapsulating a biological entity includes templating a biocompatible material onto a biological structure to form a coating structure enclosing the biological structure, the coating structure having a size in the nanometer range, in which the coated biological structure preserves its biological activity within the coating structure. In some implementations of the method, the biological structure includes a virus and the biocompatible material includes silica.
9
EP3765047A1
ONCOLYTIC VACCINIA VIRUS EXPRESSING IMMUNE CHECKPOINT BLOCKADE FOR CANCER IMMUNOTHERAPY
Publication/Patent Number: EP3765047A1 Publication Date: 2021-01-20 Application Number: 19767111.8 Filing Date: 2019-03-12 Inventor: Deng, Liang   Wang, Weiyi   Shuman, Stewart   Merghoub, Taha   Wolchok, Jedd   Yan, Wei   Assignee: Memorial Sloan-Kettering Cancer Center   IPC: A61K35/76
10
US2021121510A1
BACTERIOPHAGE COMPOSITIONS
Publication/Patent Number: US2021121510A1 Publication Date: 2021-04-29 Application Number: 17/047,611 Filing Date: 2019-04-17 Inventor: Rast, Markus   Rodriguez-morillas, Sergio   Iida, Tomomine   Assignee: TAKEDA GMBH   TAKEDA PHARMACEUTICAL COMPANY LTD.   IPC: A61K35/76 Abstract: The present invention relates to a bacteriophage composition comprising at least one bacteriophage species, at least one α-linked polymeric glucose and at least one polyol. In certain embodiments, the α-linked polymeric glucose has a mean molecular weight of greater than 10 kDa.
11
EP3010519B1
ONCOLYTIC ADENOVIRUS FOR USE IN A TREATMENT OF BRAIN CANCER
Publication/Patent Number: EP3010519B1 Publication Date: 2021-04-07 Application Number: 14736238.8 Filing Date: 2014-06-13 Inventor: Fueyo, Juan   Manzano-gomez, Candeleria   Conrad, Charles   Lang, Fred   Yung, W.k. Alfred   Tufaro, Frank   Assignee: DNAtrix, Inc.   Board of Regents, The University of Texas System   IPC: A61K35/76
12
EP3810149A1
RECOMBINANT NUCLEIC ACIDS ENCODING COSMETIC PROTEIN(S) FOR AESTHETIC APPLICATIONS
Publication/Patent Number: EP3810149A1 Publication Date: 2021-04-28 Application Number: 19792681.9 Filing Date: 2019-04-26 Inventor: Krishnan, Suma   Parry, Trevor   Agarwal, Pooja   Assignee: KRYSTAL BIOTECH, INC.   IPC: A61K31/713
13
EP3777870A1
A DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES
Publication/Patent Number: EP3777870A1 Publication Date: 2021-02-17 Application Number: 20198714.6 Filing Date: 2014-06-12 Inventor: Beadle, John   Fisher, Kerry David   Wilkinson, Blanc Christine   Assignee: Psioxus Therapeutics Limited   IPC: A61K35/76 Abstract: The present disclosure provides a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B for use in treatment of a human patient by intravenously administering a treatment cycle with multiple doses each in the range 1 x 1010 to 1 x1013 viral particles administered over a period 1 to 90 minutes, wherein a single treatment cycle is 14 days or less and said cycle comprising a first dose on day 1..
14
US2021085733A1
NOVEL AEROMONAS HYDROPHILA BACTERIOPHAGE AER-HYP-3 AND USE THEREOF FOR INHIBITING GROWTH OF AEROMONAS HYDROPHILA BACTERIA
Publication/Patent Number: US2021085733A1 Publication Date: 2021-03-25 Application Number: 16/970,052 Filing Date: 2019-02-18 Inventor: Yoon, Seong Jun   Jun, Soo Youn   Kwon, An Sung   Jung, Ji In   Kang, Sang Hyeon   Assignee: Intron Biotechnology, Inc.   IPC: A61K35/76 Abstract: The present invention relates to a Myoviridae bacteriophage Aer-HYP-3 (Accession number: KCTC 13479BP) isolated from nature, which has the ability to kill Aeromonas hydrophila bacteria and has the genome represented by SEQ ID NO: 1, and to a method of preventing and treating a disease caused by Aeromonas hydrophila bacteria using a composition containing the same as an active ingredient.
15
US2021252081A1
IMMUNOGENIC COMPOSITION
Publication/Patent Number: US2021252081A1 Publication Date: 2021-08-19 Application Number: 16/973,471 Filing Date: 2019-06-18 Inventor: Feron, Christiane Marie-paule Simone Jeanne   Giannini, Sandra   Assignee: GLAXOSMITHKLINE BIOLOGICALS SA   IPC: A61K35/76 Abstract: The present invention discloses an engineered bacteriophage capable of binding to a commensal bacterium and inserting its genome polynucleotide into the commensal bacterium, but incapable of producing progeny, incapable of carrying out a lysogenic cycle and incapable of carrying out a lytic cycle within the commensal bacterium, wherein the engineered bacteriophage comprises a genome polynucleotide including at least one gene encoding at least one heterologous antigen(s) under the control of a promoter.
16
US2021113684A1
VECTOR-BASED ATTENUATED POXVIRUS VACCINES
Publication/Patent Number: US2021113684A1 Publication Date: 2021-04-22 Application Number: 17/130,165 Filing Date: 2020-12-22 Inventor: Howley, Paul   Assignee: SEMENTIS LIMITED   IPC: A61K39/275 Abstract: The present invention relates to a composition for raising an immune response in animal which decreases the risk of chikungunya and smallpox infection, Zika virus and smallpox infection, and/or chikungunya, Zika virus and smallpox infection. The composition comprises a pharmaceutically acceptable carrier and an attenuated poxvirus, wherein the poxvirus genome comprises a nucleic acid sequence encoding the 26S subgenomic polyprotein of chikungunya virus and/or the PrME of Zika virus.
17
US11077155B2
Bacteriophage strains and their applications
Publication/Patent Number: US11077155B2 Publication Date: 2021-08-03 Application Number: 16/090,772 Filing Date: 2017-04-03 Inventor: Wojtasik, Arkadiusz   Gorecka, Elzbieta   Wojcik, Ewelina   Stanczyk, Malgorzata   Kolsut, Joanna   Klimczak, Justyna   Dastych, Jaroslaw   Siwicki, Andrzej   Schulz, Patrycja   Assignee: PROTEON PHARMACEUTICALS S.A.   IPC: A61K35/76 Abstract: New strains of bacteriophages and their applications are revealed, useful especially in fish farming.
18
EP3886593A1
BACTERIOPHAGE COCKTAIL FOR LISTERIA MONOCYTOGENES AND ESCHERICHIA COLI
Publication/Patent Number: EP3886593A1 Publication Date: 2021-10-06 Application Number: 19949570.6 Filing Date: 2019-11-12 Inventor: GÖncÜo, Lu Muammer   Ayaz, Naim Deniz   Erol, Rfan   Çufao, Lu Gizem   Assignee: Ankara Üniversitesi Rektörlügü   IPC: A23B4/22
19
US2021077551A1
THERAPEUTIC BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTION
Publication/Patent Number: US2021077551A1 Publication Date: 2021-03-18 Application Number: 16/959,666 Filing Date: 2019-01-02 Inventor: Morales, Sandra P.   Mearns, Gillian   Rankin, Deborah A.   Smrekar, Frenk   Assignee: Armata Pharmaceuticals, Inc.   IPC: A61K35/76 Abstract: The present disclosure relates to a bacteriophage composition comprising one or more (suitably two or more, or three) obligately lytic bacteriophages capable of infecting and lysing Staphylococcus aureus, and use of the same for treating Staphylococcus aureus bacterial infections.
20
US10894068B2
Bordetella bronchiseptica bacteriophage Bor-BRP-1, and use thereof for inhibition of proliferation of Bordetella bronchiseptica bacteria
Publication/Patent Number: US10894068B2 Publication Date: 2021-01-19 Application Number: 16/312,376 Filing Date: 2017-06-13 Inventor: Yoon, Seong Jun   Jun, Soo Youn   Paik, Hyoun Rok   Son, Jee Soo   Park, Suk Hwang   Kim, Byung Kuk   Kang, Sang Hyeon   Assignee: INTRON BIOTECHNOLOGY, INC.   IPC: A61K35/76 Abstract: The present invention relates to a Podoviridae bacteriophage Bor-BRP-1 (accession no. KCTC 12705BP) isolated from nature, which has an ability to specifically kill Bordetella bronchiseptica bacteria and has a genome represented by SEQ ID NO: 1; and a method for preventing and treating infection with Bordetella bronchiseptica bacteria using a composition comprising the same as an active ingredient.
Total 500 pages